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SYNOPSIS 
 
Conventional methods for the treatment of cancer include chemotherapy, surgery, radiation 
therapy, immunotherapy etc. The daunting challenge of cancer therapy is destroying tumour 
mass without affecting the near or distant body tissues or organs. To this end, anti-
angiogenic approach is an emerging and highly promising therapeutic modality to combat 
cancer. Angiogenesis is formation of new blood vesssels from pre-existing blood vessels 
(Figure 1). This is like formation of a new canal from a river to an agricultural field for 
water supply. During solid tumour formation, cancer cells divide and form a primary small 
tumour. Our body has its own pre-existing circulation network to supply food, nutrients and 
oxygen into each and every body cell. Tumor growth beyond a size of 1-2 mm3 needs 
assembly of blood vessels for supply of nutrients for the growing tumours. Tumour cells 
secret some enzymes and growth signals (cytokines) which signal nearer blood veseels to 
form sub-vessels directed toward the tumour (angiogenesis). 
Growing solid tumours extract foods and nutrients from the tumour vasculatures. 
The rationale of the anti-angiogenic cancer therapy approach is based on shutting down this 
food supply (by destroying the blood vessels) to tumour cells so that the tumour cells die 
out of starvation. Clinical success of anti-angiogenic cancer therapy thus critically depends 
upon selective delivery of cytotoxic genes/drugs to the endothelial cells of the sprouting 
new blood vessels around the tumors.  The biochemical characteristics that distinguish 
tumor blood vessels (neovasculatures) from resting vessels include expression of a number 
of angiogenesis-related molecules such as integrins, endothelial cell growth factor 
receptors, proteases, cell surface proteoglycans and extra cellular matrix (ECM) 
components.  Integrins, the major class of αβ heterodimeric transmembrane glycoprotein 
receptors, mediate cellular adhesion to ECM or to adjacent cells and can regulate cell 
survival and proliferation by modulating intracellular signaling processes.  Since many 
integrins and their specific extracellular matrix (ECM) ligands play crucial roles in 
mediating tumor angiogenesis, they are gaining increasing importance as drug targets in 
anti-angiogenic cancer therapy.  Through a series of enzymatic degradations of extracellular 
matrix proteins and binding studies with the resulting peptide fragments, Ruoslahti and 
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coworkers showed that a minimum arginine-glycine-aspartic acid (RGD) tripeptide 
sequence is required for the integrin binding property of several ECM proteins  
Anti-angiogenic cancer gene therapy: The key features of gene therapy are to supplement 
the body cells with the correct functioning copy of the malfunctioning genes. Broadly, gene 
therapy can be defined as the delivery of nucleic acids by means of a vector to patients for 
some therapeutic benefit. Stated differently, if somebody is suffering from a disease due to 
mutation in a known gene, delivery of the correct copy of this malfunctioning gene to the 
effected site or organ would be expected to correct the genetic defect and hence cure the 
disease. Since both biological cell surface and DNAs (genes) are negatively charged, entry 
of genes into our body is not a spontaneous process. In gene therapy, delivery of correct 
functioning copy of the malfunctioning genes is usually accomplished through use of 
efficient gene carrier. Currently, there are three main types of gene delivery vectors 
commonly in use: viral, non-viral and physical methods, each having its own merits and 
demerits. During last decade, our laboratory has developed a number of highly efficient 
cationic lipid based non-viral gene delivery reagents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1: A schematic animation of aniogenesis 
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Tumour suppressor genes p53: In most direct form of cancer gene therapy, tumour 
suppressor genes are delivered to cancer cells as these tumour suppressor genes are present 
in mutated forms in cancer cells. Some typical examples of tumour suppressor genes are 
p53, APC, RB, PTEN, ARF, and BRCA1. The expression of these known tumour 
suppressor genes in tumour cells causes an aberrant change in cell physiology and gene 
expression resulting cell-cycle arrest or death. Among tumour suppressor genes, the most 
common and widely used gene is p53. It encodes a protein of 53 KDa size (hence is the 
name p53). In both inherited and spontaneous cancer, p53 is found till date as the most 
commonly mutated gene in human tumour. The function of p53 and its protein product is to 
prevent normal cells from turning into cancer cells. Inhibition of tumour growth can be 
achieved by delivering wild type p53 gene (in the form of a plasmid) selectively to either 
cancer cells or to the endothelial cells of growing tumour vasculature. Expression of wild 
type p53 increases the probability of apoptosis in treated tumours and it has now been 
demonstrated that delivery of p53 can kill cancer cells in vivo. 
 
RNA interference: Discovery of small non-coding RNAs is changing the protein-centric 
view of molecular cell biology.  There are three main types of “classic” RNA namely, 
messenger RNA (mRNA), transfer RNA (tRNA) and ribosomal RNA (rRNA).  mRNAs are 
RNAs which mediate translation by acting as templates for protein synthesis.  rRNAs are 
the RNA constituents of the ribonucleoprotein particles known as ribosomes which mediate 
decoding of mRNA to the amino acid sequences of proteins and tRNAs are the adapter 
molecules carrying individual amino acids to the site of protein synthesis that recognize 
specific codons in mRNA.   Stated differently, mRNAs get translated into proteins while 
tRNAs and rRNAs carry out the house keeping roles during mRNA translation.  In contrast, 
small RNAs are not translated into proteins.  During the past two to three decades, scientists 
have identified approximately 70-300 nucleotide long small regulatory RNAs in various 
organisms.  But small RNAs ranging in size from 20 to 30 nucleotides have been 
discovered more recently. These 20-30 nucleotide long small RNAs are classified broadly 
into three categories: small interfering RNAs (siRNAs), microRNAs (miRNAs) and Piwi-
associated RNAs (piRNAs).   
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Figure 2: Formation and function of small RNAs. 
 
As to how the small RNAs control expression of genes, they recognize their mRNA 
targets by sequence-specific base pairing.  One siRNA strand assembles into an effector 
complex known as RNA induced silencing complex (RISC) which uses siRNA as a guide 
to identify the target mRNA possessing the perfectly complementary sequence to the 
siRNA.  The subsequent outcome of the small RNA-mRNA association is dictated by the 
degree of complementarity between the two sequences.  When the base-pairing is perfect, 
or almost perfect (as is the case for siRNAs and possibly piRNAs), the target mRNA is 
cleaved in the middle of the small RNA-mRNA duplex.  Most plant miRNAs and some 
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animal miRNAs function similarly.  However, majority of the animal miRNAs base-pair 
imprecisely with their target mRNAs to repress their translation or to induce mRNA 
degradation.  Importantly, irrespective of their base-pairing precisions, small RNAs rely on 
proteins of the Argonaute family for their activities.  It is these protein partners of small 
RNAs that bring about repression of translation or induction of mRNA degradation (Figure 
2). 
The above mentioned emerging RNA interference technology is being used as 
therapeutic tool to combat cancer. Researchers are developing small interfering RNA 
(siRNA) or miRNA which can target an mRNA of an oncogene. This is not mandatory that 
siRNA/miRNA should be designed toward an mRNA of oncogene to arrest cancer. 
siRNA/miRNA could be designed against mRNAs encoding proteins involved in the 
mechanistic pathway for the cancer growth. Through interference with siRNA/miRNA, 
cancer growth can be inhibited. To prevent tumour growth by RNA interference, one needs 
to succeed in delivering a properly designed siRNA or miRNA capable of inducing cell 
death or cell cycle arrest in tumour or in tumour endothelial cells. 
JAK-STAT Pathway: The development of all organisms requires execution of highly 
controlled complex programs whereby specific genes are activated and repressed in specific 
sets of cells maintaining a precise time sequence.  Even mature cells (which are part of a 
differentiated tissue) constantly change their gene expression patterns.  Such changes in 
gene expression are induced by extracellular signaling molecules those act on different cell-
surface receptors. Among the multitude of signal transduction mechanisms, the Janus 
kinase (JAK)-Signal Transducer and activator of transcription (STAT) signaling pathway 
plays a crucial role in various physiological processes including immune function, cell 
growth, differentiation, and hematopoiesis. The phosphorylated STAT then spontaneously 
dissociates from the receptor and gets spontaneously dimerized.  The resulting STAT-dimer 
with two exposed nuclear localization signals (NLS), get translocated into the cell nucleus 
where it can bind to promoter sequences and activate transcription of genes. Different 
STATs activate different genes in different cells.  For instance, stimulation by 
erythropoietin in erythroid progenitor cells leads to activation of STAT5.  The major 
protein expression induced by active STAT5 is Bcl-xL, which prevents programmed cell 
death (apoptosis) of these progenitors, allowing them to proliferate and differentiate into 
 VI
erythroid cells.  In addition to their diverse biological functions in cell proliferation, 
differentiation, apoptosis, inflammation and oncogenesis, recent findings are consistent 
with the supposition that STATs mainly, STAT3, plays important roles in angiogenesis 
under both physiological and pathological conditions. 
Targeted Liposomes and RGD: Targeted liposomes possess a covalently grafted targeting 
moiety in the head group region of amphiphiles. This targeted moiety is usually a ligand for 
various cell surface receptors. The targeting moieties which are grafted on the liposomal 
surface are generally of two types, either an antibody against a specific antigen of cells or a 
small molecule ligand for a receptor which is over-expressed in a given cell. Several 
receptors which are overexpressed in human malignancies are exploited in targeted 
liposomal cancer gene therapy. It has been discussed earlier about the role of RGD in terms 
of its integrin binding property. As integrins are overexpressed in various cancer cells and 
in angiogenic endothelial cells, grafting RGD in liposomal head group and use of RGD 
associated liposomes in tumour targeted gene therapy have found wide therapeutic 
exploitations (131-133).  Since sprouting angiogenic endothelial cells overexpress integrin 
receptors, targeting tumour endothelial cells with RGD-liposomes loaded with anti-cancer 
drugs/genes is an attractive therapeutic strategy. 
Present Thesis: 
Chapter 1A: Clinical success of antiangiogenic cancer therapy critically depends upon 
selective delivery of cytotoxic genes/drugs to the endothelial cells of the sprouting new 
blood vessels around the tumours.  Potential targets include mediators of angiogenesis and 
protein molecules over expressed in the endothelial cells of tumour neovasculatures. 
Integrins, the αβ heterodimeric transmembrane glycoprotein receptors, belong to such class 
of molecules which play crucial roles in mediating tumour angiogenesis.  Gene ablation 
experiments combined with use of antibodies/peptide ligands have convincingly 
demonstrated α5β1 integrin to be the most proangiogenic among these three integrin 
receptors.  The findings delineated in Chapter 1A demonstrate for the first time that 
lipopeptide containing a lysine functionality after the RGD sequence in its polar head-group 
region (RGDK-lipopeptide 1, Fugure 3) can selectively target genes to the proangiogenic 
α5β1 integrin receptors. Chol-RGDK-lipopeptide 3 (Figure 3) also showed α5β1 integrin 
receptor selective gene transfer efficiency in A549 cells. Thus, the α5β1 integrin receptor 
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speficity of the RGDK-lipopeptide was found to be independent of the nature of its 
lipophilic constituent.  When the lysine residue of the RGDK tetrapeptide sequence was 
replaced with a leucine or arginine residue, the resulting RGDL-lipopeptide 4 (Figure 3) or 
RGDR-lipopeptide 5 (Figure 3) did not show any α5β1 integrin receptors selective 
transfection properties. This demonstrates that the lysine functionality in RGDK-
lipopeptide 1 plays a crucial role behind its α5β1 integrin receptor specificity. 
Immunohistochemical staining of mice tumour sections revealed efficacy of RGDK-
lipopeptide 1 in delivering genes to tumour vasculatures.  Importantly, remarkable 
inhibition of tumour growth was observed when the electrostatic complex of the RGDK-
lipopeptide 1 and the anti-cancer p53 gene was intravenously administered in C57BL/6 
mice bearing aggressive B16F1 tumour. Availability of the presently described RGDK-
lipopeptide 1 is expected to find future clinical exploitation in anti-angiogenic cancer 
therapy including non-invasive imaging of tumour vasculatures. 
Chapter 1B: As mentioned above, the findings delineated in Chapter 1A, demonstrate for 
the first time that lipopeptide containing a lysine functionality after the RGD sequence in its 
polar head-group region (RGDK-lipopeptide 1) can selectively target genes to the 
proangiogenic α5β1 integrin receptors and can deliver genes to tumour neo-vasculature. 
The findings described in Chapter 1B demonstrate that the RGDK-lipopeptide 1:STAT3 
miRNA (pAmiR_STAT3) can inhibit STAT3 protein synthesis and hence can induce 
apoptosis of when delivered to A549 cells. Importantly, remarkable inhibition of tumour 
growth was observed when the electrostatic complex of the RGDK-lipopeptide 1 and the 
STAT3 miRNA was intravenously administered in C57BL/6 mice bearing aggressive 
B16F1 tumour. Immunohistochemical studies further confirmed apoptosis of tumour 
vasculature only when STAT3 miRNA was administered with RGDK-lipopeptide 1. To 
conclude RGDK-lipopeptide 1:STAT3 miRNA complex is expected to find future clinical 
exploitation in anti-angiogenic cancer therapy specially in terms of delivering anti-
angiogenic miRNA. 
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Figure 3. Structures of the newlydesigned RGD-lipopeptides used in the present study
 IX
Chapter 2: The findings described in Chapter 2 delineates the development of a novel 
histidinylated cationic amphiphiles (HL-16, Figure 4) capable of blocking integrin-ligand 
interaction. Using liposomal formulation of four histidinylated cationic amphiphiles with 
varying hydrophobic tails (HL-8, HL-10, HL-14, HL-16) we have shown that liposomal 
formulation of this HL-16 is capable of inhibiting tumour growth under systemic settings. 
TUNEL assay confirmed apoptosis inducing ability of HL-16 liposomes. 
Immunohistochemical studies confirmed that apoptosis of both tumour endothelial cells and 
tumour cells are induced when HL-16 liposomes were intratumourally administered in 
C57BL/6 mice bearing B16 melanoma. Blood vessel staining of tumour cryosections 
revealed significant reduction of blood vessel density in HL-16 liposomes treated tumour. 
Taken together, the findings delineated in Chapter 2 demonstrate for the first time that 
histidinylated cationic amphiphiles are a promising new class of reagents for future use in 
anti-angiogenic Cancer Therapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4: Structure of histidinylated cationic amphiphiles. 
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